PB2310: CHIDAMIDE WITH AZACITIDINE AND CHOP TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED PERIPHERAL T-CELL LYMPHOMA:INTERIM ANALYSIS OF A PROSPECTIVE,SINGLE CENTER,SINGLE-ARM, PHASE 2 TRIAL
Authors: Chunyan Xiao, Yao Ding, Chensi Zeng, Yingyu Nan, Yao Liu
Journal: HemaSphere (2023)

Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: The standard first-line treatment for peripheral T-Cell Lymphoma (PTCL) is cyclophosphamide, doxorubicin, vincristine, and prednison (CHOP),but the treatment effect is poor,the 5-year overall survival(OS) was only 30-40%. Aims: We aimed to evaluate the efficacy and safety of chidamide with azacitidine and CHOP treatment plus autologous stem-cell transplantation(auto-ASCT) and of maintenance treatment with chidamide in newly diagnosed PTCL. Methods: This is an ongoing prospective,single center,single-arm, phase 2 trial. We enrolled newly diagnosed PTCL patients (NK/T lymphoma and ALK positive anaplastic large cell lymphoma were excluded)and used 21-day Chi+AZ-CHOP regimen for induction therapy.Subjects received CHOP on day 1 combined with azacitidine 100mg was subcutaneous injected daily for 5 days and oral chidamide 20mg two times per week of each cycle. 7 subjects received PEG-rhG-CSF Supportive care after treatment.These subjects who evaluated PR or CR remission after 4 to 6 courses of induction therapy will perform autologous hematopoietic stem cell transplantation(ASCT), followed by oral chidamide 20mg two times per week maintance. The primary endpoints is ORR per 2014 IWG criteria.Secondary endpoints include CR, safety and survival. Results: From 3/2021 to 12/2022, 23subjects with previously untreated PTCL were enrolled in chongqing university cancer hospital, and the study met its accrual.At study entry, 16 patients (69.5%) were angioimmu-noblastic T-cell lymphoma(AITL),4 patients (17.4%) were Peripheral T Cell Lymphoma, Not Otherwise Specified(PTCL-nos),1 patient(4.3%) was monomorphic epitheliotropic intestinal T-cell lyphomas(MEITL),1 patient(4.3%) was Mycosis fungoides(MF),1 patient(4.3%) was anaplastic large cell lymphoma; ALK-negative(ALCL-ALK). The median age was 57 years (range 27-70),and the M:F ratio was 1.3:1. Eighty two (82%) had stage III/IV disease, 6 (26%) had bone marrow involvement, and 14(61%) had IPI 3-5.By July 2022, 1 subject did not return to the hospital for further treatment after the first cycle. 19 subjects received Chi+AZ-CHOP regimen treatments at least 2 cycles,median treatment cycles were 4 cycles.3 subjects progressed during the treatment, 8 subjects were performed with autologous hematopoietic stem cell transplantation. the ORR was 84.2% with CR at 42.1%.The assessment after autologous hematopoietic stem cell transplantation(n=8), ORR was 100 % and CR was 75%.To date, Evaluation of outcomes in patients with AITL at the end of induction(n=13), one of the subjects did not return to the hospital for further treatment after the first cycle,ORR was 92.3% and CR was 61.5%. Treatment was generally well tolerated with expected side exects.The most common grade 3-4 hematologic adverse events were neutropenia(47.8%),febrile neutropenia (39.1%),anemia (26%) and thrombocytopenia (26%),Grade 3-4 non-hematologic toxicities included hypokalemia(30.4%),nausea(34.8%), vomiting (21.7%),fatigue (34.8%),and elevated ALT (4.8%).No treatment-related deaths have been studied so far. Summary/Conclusion: This trail proved that chidamide combined with azacytidine +CHOP is feasible and safe in the treatment of peripheral T-cell lymphoma. Especially,achieved a high CR rate in the induction therapy phase of AITL subtype. Although neutropenia is the most common adverse reaction, it is generally safe and controllable.Keywords: Peripheral T-cell lymphoma, Phase II, Clinical trial